<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485223</url>
  </required_header>
  <id_info>
    <org_study_id>15022 [Sponsor reference]</org_study_id>
    <secondary_id>15/NW/0286</secondary_id>
    <nct_id>NCT02485223</nct_id>
  </id_info>
  <brief_title>Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis</brief_title>
  <acronym>STAR-MS</acronym>
  <official_title>Single Test to ARrive at MS Diagnosis. A Prospective, Longitudinal, Investigator Blinded, Pilot Study Assessing the Accuracy of a Single 3 Tesla MRI Scan in Predicting Multiple Sclerosis in Cases of Diagnostic Uncertainty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study (a small scale study testing procedures so that the investigators can
      apply this to a larger scale study). This study will test the accuracy of a new brain scan
      (Magnetic Resonance Imaging) technique in predicting the diagnosis of multiple sclerosis (MS)
      in patients where there is uncertainty about the diagnosis. For patients where there is a
      suspicion (but not definite) diagnosis of MS, an additional MRI brain scan will be offered.
      There will be no other research tests and the patient is followed up to see what the eventual
      diagnosis is. The investigators will then review the original brain scan to see if this
      predicted the diagnosis of MS or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no single, simple test to differentiate MS from conditions that mimic it. Apart from
      the patient's symptoms, doctors use Magnetic Resonance Imaging (MRI) of the brain to see if
      there are abnormalities which are consistent with MS. In patients without typical symptoms or
      a typical MRI appearance, a firm diagnosis cannot be made as other neurological illnesses can
      mimic symptoms of MS and the MRI scans can look very similar. Further tests are often
      required such as lumbar punctures, resulting in delays, discomfort for the patient and
      additional healthcare costs. With time the diagnosis can become clearer as patients may
      develop other symptoms of MS but this may take months or years.

      The most common errors are from misinterpretation of the brain abnormalities or 'lesions'
      seen on the MRI scan. Subsequently if a patient is misdiagnosed with MS they may receive
      treatment they do not need. Furthermore a delay in a firm diagnosis delays treatment for
      another condition. With the rapid increase of new medications in the last few years, accurate
      and rapid diagnosis is paramount.

      Pathologically (when looking at lesions using a microscope) MS lesions usually have a vein
      running through the centre, whereas in lesions arising from other conditions, the
      investigators hypothesize that no central vein is seen. The investigators can therefore
      distinguish between patients with MS and patients without it.

      The researchers therefore want to test the value of a clinical 3-Tesla MRI brain scan in
      accurately distinguishing between MS and other conditions, with MRI sequences that have been
      refined over the last few years.

      Patients will only have one research MRI brain scan and then be followed up by their
      neurologist, who will confirm the final diagnosis. The investigators shall then look back at
      the original scans to see if those with MS had veins within their lesions and if those
      without MS had lesions without veins
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the proportion of central veins:lesions in patients with MS and non-MS.</measure>
    <time_frame>After 1 year of follow up with a confirmed diagnosis.</time_frame>
    <description>To detect this difference with an alpha of 0.05 and power of 0.8, (based on previous data that shows a mean proportion of approx. 60% in MS patients and 6% in ischaemic patients) we will need 12 patients with MS and 12 with non-MS at 1 year of follow up. However given the fact that approx. 40% of patients will have a diagnosis of MS at 1 year, we will need to scan 60 patients in total.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of using a proportion of central veins:lesions in diagnosing MS.</measure>
    <time_frame>After 1 year of follow up with a confirmed diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of using a proportion of central veins:lesions in diagnosing MS.</measure>
    <time_frame>After 1 year of follow up with a confirmed diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of the central vein:lesion MRI test.</measure>
    <time_frame>After 1 year of follow up with a confirmed diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of the central vein:lesion MRI test.</measure>
    <time_frame>After 1 year of follow up with a confirmed diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal proportion of central veins:lesions to make a diagnosis of MS.</measure>
    <time_frame>After 1 year of follow up with a confirmed diagnosis.</time_frame>
    <description>Receiver Operating Characteristic (ROC) curves will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patient recruitment.</measure>
    <time_frame>After 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohen's kappa inter-rater agreement for the diagnosis of MS using the MRI test.</measure>
    <time_frame>After 1 year of follow up.</time_frame>
    <description>Can different observers calculate the same proportion of central veins:lesions on each scan.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators will recruit patients who attend the general neurology and MS clinics at
        Nottingham University Hospitals (NUH) NHS Trust, UK. The researchers anticipate that the
        study population will comprise of two groups: the common presentation of young individuals
        following the first neurological symptoms suggestive of MS, however the neuroradiologist's
        report of the MRI will not be in agreement with the neurological impression; and a group of
        patients who present with atypical symptoms for MS but the MRI scan is reported as
        suggestive of MS.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to tolerate an MRI brain scan

          -  No contraindications to MRI

          -  Radiological suspicion of MS, but clinically atypical or Clinical suspicion of MS, but
             radiologically atypical

          -  Radiological or clinical suspicion of any of the following with a routine MRI brain
             scan showing white matter lesions; Autoimmune/Inflammatory; Antiphospholipid syndrome,
             Neurosarcoidosis, Neuro-Behcet's disease, Neuromyelitis Optica, Systemic lupus
             erythematosus, Primary CNS vasculitis, Secondary CNS vasculitis, Sjogren's syndrome,
             Susac syndrome. Ischaemic; Hypertensive ischaemic disease (small vessel disease),
             embolic disease. Infective ; Lyme disease, Cytomegalovirus CNS infection,
             Toxocariasis, Neurocysticercosis, Whipple's disease, Progressive Multifocal
             Leukoencephalopathy, Herpes virus (HHV) infection e.g VZV, HIV, Toxoplasmosis,
             Tuberculosis, Neurosyphilis. Neoplastic; Lymphoma, Glioma, Primary CNS Lymphoma,
             Cerebral metastases. Other; CADASIL, Histiocytosis, Migraine, Mitochondrial disease,
             Leukodystrophy.

        Exclusion Criteria:

          -  Unable to tolerate a further MRI scan

          -  Unsafe to perform an MRI scan

          -  Pregnancy

          -  Participants with normal routine clinical scans

          -  Unable to give written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Nikos Evangelou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Neurology, Division of Clinical Neuroscience, University of Nottingham, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Neurology, Division of Clinical Neuroscience, University of Nottingham, UK</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Tallantyre EC, Brookes MJ, Dixon JE, Morgan PS, Evangelou N, Morris PG. Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI. Neurology. 2008 May 27;70(22):2076-8. doi: 10.1212/01.wnl.0000313377.49555.2e.</citation>
    <PMID>18505982</PMID>
  </reference>
  <reference>
    <citation>Tallantyre EC, Dixon JE, Donaldson I, Owens T, Morgan PS, Morris PG, Evangelou N. Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. Neurology. 2011 Feb 8;76(6):534-9. doi: 10.1212/WNL.0b013e31820b7630.</citation>
    <PMID>21300968</PMID>
  </reference>
  <reference>
    <citation>Mistry N, Dixon J, Tallantyre E, Tench C, Abdel-Fahim R, Jaspan T, Morgan PS, Morris P, Evangelou N. Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain. JAMA Neurol. 2013 May;70(5):623-8. doi: 10.1001/jamaneurol.2013.1405.</citation>
    <PMID>23529352</PMID>
  </reference>
  <reference>
    <citation>Sati P, George IC, Shea CD, Gait√°n MI, Reich DS. FLAIR*: a combined MR contrast technique for visualizing white matter lesions and parenchymal veins. Radiology. 2012 Dec;265(3):926-32. doi: 10.1148/radiol.12120208. Epub 2012 Oct 16.</citation>
    <PMID>23074257</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>Diagnostic test</keyword>
  <keyword>Central veins</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

